‘Strikingly better’: Co-antibody combination tops golimumab, guselkumab in refractory IBD

CHICAGO — Combining golimumab and guselkumab into JNJ-78934804, a fixed-dose co-antibody therapy, helped overcome treatment failure in inflammatory bowel disease and exceeded dose-dependent benefits of either drug alone, according to data.Two parallel phase 2b trials combining the anti-tumor necrosis factor and anti-interleukin-23 medications in Crohn’s disease and ulcerative colitis,